Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion received Phase 3 Clinical Trial Application (CTA) (Part 1 & Part 2) approval from the European Medicines Agency (EMA) for CT-P51, a biosimilar candidate referencing Keytruda, targeting patients with metastatic non-squamous non-small cell lung cancer.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: European EMA Approval of Phase 3 Clinical Trial Plan (Part 1 & Part 2) for CT-P51 (Keytruda Biosimilar)
- Regulatory Authority: European Medicines Agency (EMA)
- Key Dates (Local Time): Application Date 2024-08-22 / Approval Date 2024-12-12
- Confirmation Date: 2024-12-13 (Date approval was confirmed via CTIS)
- Clinical Trial Details
- Study Title: A Double-Blind, Randomized, Active-Controlled, Phase 3 Trial to Compare the Efficacy and Safety of CT-P51 and Keytruda in Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase: Global Phase 3
- Target Indication: Non-Small Cell Lung Cancer (NSCLC)
- Registration Number: EU CT number 2024-514048-98-00
- Patient Count: 606 subjects
- Duration: 2-year treatment period
- Purpose: To compare efficacy and safety between CT-P51 and the reference drug Keytruda to demonstrate biosimilarity
- Regulatory Process & Investment Risks
- This disclosure covers simultaneous approval for both Part 1 (assessment of trial design and methodology) and Part 2 (assessment of trial sites and execution) under revised EU Clinical Trials Regulations, clearing all regulatory requirements to initiate clinical trials.
- Celltrion plans to demonstrate biosimilarity to Keytruda and seek approval across all reference indications including non-small cell lung cancer.
- Statistically, the probability of a clinical-stage drug candidate receiving final authorization is approximately 10%. Commercialization plans may be altered or abandoned based on trial outcomes.
- Content of this disclosure will be utilized in upcoming press releases and IR materials.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Clinical Trial Progress and Patient Dosing in Europe
This disclosure serves as official notification that Celltrion has received European EMA approval for its Phase 3 Clinical Trial Plan (Part 1 & 2) for CT-P51. Tracking whether patient enrollment and first patient dosing proceed according to schedule is important for evaluating the execution of the approved trial plan. Relevant updates can be confirmed through subsequent periodic reports or official IR announcements.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
